Background: Chemoradiation (CRT) or short-course radiotherapy (SCRT) are
Background
Preoperative CRT followed by TME has become the international standard treatment for patients with LARC. CRT improves local control, but has failed to enhance overall survival (OS). Tumor down-staging is achieved in only 50%, and a pCR in 10e25%. CRT delivers low doses of chemotherapy, and delays administration of effective systemic chemotherapy by 4e6 months Up to 30% of patients with LARC still subsequently develop metastatic disease [1] . Pelvic radiotherapy is associated with an increased risk of postoperative wound complications and long-term adverse late-effects (gastrointestinal, urological, psycho-sexual symptoms and chronic pain) and an increased risk of second malignancy. Recent improvements in the quality of surgery have also led to low local recurrence rates without radiation.
MRI can define the maximal extramural depth (EMD) of radial tumor spread from the breached muscularis propria in a sub-classification of T3 tumors i.e. mrT3a ¼ <1 mm, mrT3b ¼ 1$01-5$00 mm, mrT3c ¼ 5$01-15$00 mm and mrT3d ¼ >15$01 mm, the distance to the mesorectal fascia and extramural venous invasion (EMVI). Hence, risk adaptive strategies might be envisaged whereby chemotherapy or radiotherapy is selected according to the relative risks of local or distant recurrence.
In contrast to postoperative adjuvant chemotherapy, compliance with NACT is high [2] . In the Grupo C ancer de Recto 3 study [3] 92% patients received full systemic doses in the induction arm prior to CRT, compared with only 51% in postoperative adjuvant arm (p ¼ 0.0001).
In colon cancer, the earlier the adjuvant chemotherapy following surgery, the more effective it is [4] . In rectal cancer, the optimal time to start chemotherapy may be within 5e6 weeks [5] , but surgical morbidity can delay delivery and increase the risk of distant metastases [6] .
Triplet schedules (FOLFOXIRI) with or without biological agents demonstrate high response rates in metastatic disease, which led us to randomise between FOLFOX and bevacizumab, and FOLFOXIRI and bevacizumab in the neoadjuvant setting. The BACCHUS study examines the potential benefit of doublet (FOLFOX) and triplet (FOLFOXIRI) chemotherapy regimens in combination with bevacizumab, and investigated whether intensive NACT alone without radiotherapy can be tolerable with acceptable toxicity. We hoped to achieve a pCR rate in primary rectal cancer sufficient to warrant further investigation in a phase III study comparing current standards of SCRT and/or 5FU based chemoradiotherapy with NACT alone.
Methods
This multicentre, open-label, prospective, randomised phase II study (NCT01650428) was approved by Riverside l Research Ethics Committee (ref:12/ LO/1158), and sponsored by University College London. All participants provided written informed consent before inclusion in the trial.
In terms of the population of the study, patients with histologically confirmed MRIdefined high-risk resectable adenocarcinoma of the rectum and World Health Organisation (WHO) performance status of 0e1 with no distant metastatic disease were recruited. High-resolution thin-slice MRI (3 mm) was mandated for loco-regional staging. Other eligibility criteria included distal tumour 4e12 cm from the anal verge, with a predicted penetration of the muscularis propria by >1 mm extension (i.e. minimum of cT3b) or T4a; cN2, and EMVI. Patients with tumour or suspected involved lymph nodes extending to within 1 mm from, or breaching the circumferential resection margin (CRM) were excluded.
The study objective was to demonstrate the efficacy and safety of NACT alone in LARC. The primary endpoint was pCR. Secondary endpoints included safety, tolerability and feasibility of delivering FOLFOX/FOLFOXIRI/Bevacizumab; overall response rate (ORR), CRM negative (R0) resection rate, T and N stage downstaging, Progression-free survival (PFS), Disease-free Survival (DFS), OS, local control, 1 year colostomy rate, adverse events, compliance with chemotherapy treatment, and tumour regression grade (TRG).
The completion rate of the neo-adjuvant treatment, pCR frequency, number of patients with a R0 resection were recorded. Adverse events were recorded and graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version v4.03.
We also used NAR score as a composite endpoint [7, 8] using a weighted combination of final pathological nodal stage (ypN) and down-staging of T stage (mrT stage to ypT stage) representing a pseudo-continuous variable with 24 possible discrete scores, ranging from 0e100 [8] .
Patient randomisation was performed centrally at the UCL trials centre and patients were randomly assigned to one of two treatment arms using a minimisation algorithm in a 1:1 ratio and stratified according to treating centre, gender and presence or absence of EMVI.
The primary endpoint was pCR (ypT0N0). We considered a likely pCR rate of 15e20 % after standard fluoropyrimidineebased CRT and 4% with radiotherapy alone. The study was powered on the assumption that NACT would achieve a pCR rate of 20%. Hence, with a type I error a ¼ 0$05 and a type II error b ¼ 0$8, then 27 patients for the FOLFOX/Bevacizumab arm were required, and the same number for the FOLFOXIRI/Bevacizumab arm. Assuming 10 % of patients will be non-evaluable, 30 patients were to be recruited to each arm (i.e. a total of 60 patients). NACT would be considered promising and worth exploring further in a randomised phase III trial if at least 4/27 pCRs (15%) were observed in each arm. The trial was not powered to perform any direct comparisons between the two arms.
Both arms delivered chemotherapy (FOLFOXIRI or FOLFOX) preoperatively with bevacizumab every 2 weeks to a total of 6 cycles (bevacizumab omitted during cycle 6 i.e. the final chemotherapy cycle before resection). See Fig. 1 for Treatment schedule. Dose modifications for toxicity were permitted according to specified protocol guidelines. Adverse events were monitored from informed consent to 3 months after surgery. The assessment of response and progression was based on investigator-reported measurements, which were subsequently centrally reviewed. Evaluation of SUV changes in primary tumour with PET/CT was mandated prior to cycle 4. Response was defined as a decrease in SUV by 30% after 3 cycles compared to baseline. Patients who failed to respond came off trial, and were treated at investigators discretion, but were expected to receive CRT prior to surgery. Patients also underwent clinical response evaluation with MRI prior to cycle 4 and prior to surgery according to the Response Evaluation Criteria in Solid Tumours (RECIST 1.1).
Surgery was specified as TME and performed between a minimum of 6 weeks after the end of chemotherapy or 8 weeks after bevacizumab (>2 half-lives of bevacizumab) to a maximum of 10 weeks after last administration of trial treatment. Surgical morbidity was recorded with particular emphasis on anastomotic leakage and perineal wound complications.
Pathological evaluation of resected specimens was performed according to the 3 rd edition of the Royal College of Pathologists' guidelines using the 5th edition of TNM [9] . In addition, to compare with mrT-substaging, ypT3 disease was subdivided into ypT3a, ypT3b, ypT3c and ypT3d disease according to the radial outgrowth from the breached muscularis propria. pTRG is presented as data categorised into five groups-pTRG 0, pTRG 1, pTRG 2, pTRG 3, and pTRG 4 using the Dworak categories. Also, the quality of the resected specimen was evaluated with separate scoring for the mesorectum and the anal canal (in abdominoperineal excisions). pCR was defined as complete regression in the primary tumour and associated lymph nodes (ypT0 ypN0) following embedding of the entire scar and examination of at least three deeper levels per block, in keeping with RCPath guidance.
Postoperative adjuvant chemotherapy was permitted according to local protocols. Patients were followed every 6 months to 42 months after randomisation, to document recurrence and survival. Postoperative investigations/surveillance were performed according to local practice, but with a minimum of 2 CT scans in the first 2 years. Progression-free survival (PFS) was defined as time from randomisation to disease progression or death, whichever occurs first. Disease-free survival (DFS) was defined as the time from surgery with complete resection (R0) to relapse, second colorectal primary or death from any cause, whichever occurred first.
Results
The study intended to recruit 27 patients in each arm. In the event seven sites in the UK randomised 20 patients (10 in each arm) between May 2013 and August 2015.
Median age was 58 years. The trial stopped early because of poor accrual. Patient baseline characteristics in the two groups are similar (Table 1 ). See Fig. 2 for Consort diagram.
A total of 8 (80%) patients in Arm 1 and 9 (90%) in Arm 2 completed all 6 intended cycles of NACT. Three patients discontinued treatment early: one patient (Arm 2)
had not responded after 3 cycles, one (Arm 1) stopped treatment because of a myocardial infarction during cycle 1 and one (Arm 1) committed suicide after 4 cycles of treatment. There were no toxicity related deaths. The percentage dose delivered in relation to the planned dose for chemotherapy and bevacizumab was good (see compliance in Table 2 ). Table 3 shows the percentage total dose delivered by 
Note: All patients were Class I for New York Heart Association Classification at baseline.
chemotherapy drug. Median duration of NACT treatment was 72$5 days (range: 2e107) and 86$5 days (range: 30e117) in Arm 1 and Arm 2 respectively. Table  4 shows that treatment delays due to adverse events were more common amongst patients in Arm 2 (60% versus 40%) but this did not impact on the delivered total dose for any patient. Table 5 lists all the treatment-related grade 1e4 adverse events during the study.
Twelve patients had at least 1 Grade 3 adverse event, and two patients G4 (one G4 neutropenia). Table 6 shows the Acute Toxicity from NACT Bevacizumab. 
Total number of chemo cycles given
Total number of Bevazizumab cycles given
No response following 3 cycles 0 (0%) 1 (10%) (80%) in FOLFOXIRI had a reduction equal or greater than 30% in the SUV after cycle 3 compared with baseline.
Seventeen patients had tumour in the mid-rectum (>5e10 cm) and 3 in the upper rectum (from >10 cm). Radical surgery was performed in 18/20 patients: anterior resection (14), abdominoperineal excision of the rectum (3) and Hartmann' procedure (1). Surgery was not performed in one patient due to suicide and one patient refused. Both had received FOLFOX and bevacizumab. Amongst patients who had surgery in the FOLFOX arm, the median time from end of chemotherapy to surgery was 59$5 days (range: 43e154 days). All patients in the FOLFOXIRI arm had surgery with a median interval of 52$5 days (40e191 days). Of the 18 patients who proceeded to surgery esee Fig. 2 for consort diagram e 17/18 (94%) achieved an R0 resection. A total of 2/18 (11%) patients had a pCR (both in the FOLFOXIRI arm).
There were no life-threatening episodes from surgical morbidity (Table 7) , and no post-surgical deaths, although one patient developed an adhesional bowel obstruction 1 month after surgery. There was no evidence the addition of bevacizumab adversely affected surgical morbidity.
T and N down-staging were observed. The median NAR score in evaluable patients was 14$9 with 5 (28%), 7 (39%), and 6 (33%) patients having low, intermediate, and
high scores. NAR scores after NACT are shown for each arm in Table 9 , Fig. 4 . At the time of the analysis, the median follow-up time was 33$7 months In Arm 1, three deaths were reported, of which one was suicide and two due to disease progression, one of which related to a second malignancy (malignant melanoma). Two other patients in Arm 1 progressed, one patient refused surgery and received brachytherapy but subsequently relapsed at the primary site, and the other in liver. In Arm 1, the 2-year OS rate was 80% (95% CI: 41%e95%) and the 2-year PFS rate 60% (95% CI: 25%e83%).
No deaths or progressions were reported in Arm 2. OS and PFS survival curves by arm are shown in Figs. 5 and 6.
The results of imaging with PET, mriTRG and MRI diffusion weighted imaging and RECIST, TRG and tumour cell density along with the translational results will be presented in a separate report. 
Discussion
To our knowledge, the BACCHUS trial is the only NACT clinical trial which has investigated the combination of a triplet-chemotherapy backbone with bevacizumab in patients with rectal cancer. Because accrual ended early, neither of the 2 study arms met the primary endpoint of achieving a pCR of 4/27 (15%). On this basis, neither of the investigational strategies appear to merit further investigation. Nevertheless, the trial provides important data, not least because Arm 2 (FOLFOXIRI and bevacizumab) showed a pCR of 2/10 (20%) in a high-risk group where 5/10 (50%) had baseline mrEMVI (an independent prognostic factor for poor outcomes in rectal cancer).
The FOLFOXIRI plus bevacizumab arm is also promising in terms of RECIST response, pathological down-staging, pCR and the low NAR scores. Other retrospective data indicate better clinical and pathological responses after NACT combined with bevacizumab compared with NACT alone [10] . A recent metaanalysis of targeted agents added to neoadjuvant therapy in rectal cancer suggested that bevacizumab enhances the pCR rate with a pooled estimate of 27% (95% CI, 21e34%) [11] .
We have shown that NACT with FOLFOX and bevacizumab or FOLFOXIRI and bevacizumab without preoperative SCRT or CRT in patients with localised but high-risk rectal cancer is safe, with acceptable toxicity. There have been concerns regarding excessive surgical morbidity with intensive NACT e if bevacizumab is administered, and particularly when combined with preoperative radiation, but in BACCHUS there was no increase in anastomotic leaks, pelvic sepsis or fistulae, even with the addition of bevacizumab. Neither diarrhoea nor neutropenia were enhanced with the addition of irinotecan in Arm 2 (FOLFOXIRI þ Bevacizumab), although 4/10 experienced some hair loss.
The primary endpoint was pCR in the TME specimen. We had hoped the BACCHUS regimens would produce a pCR rate comparable to CRT, but only 2/ 18 (11%) achieved pCR (both received FOLFOXIRI þ bevacizumab). FOLFOXIRI and bevacizumab appears active as 4/10 (40%) achieved a complete clinical response. Other studies of NACT alone with and without bevacizumab in rectal cancer have reported higher pCR rates after NACT alone with a range of 7%e25% (Table 10 ) [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24] , but some have included more liberal entry criteria, less advanced tumours and less in-depth pathology assessment without a defined dissection protocol for pCR. The NAR score was developed from the NSABP-R04 trial data as a measure of down-staging and as a surrogate endpoint for clinical trials involving CRT [7] .
Data from 1,479 patients within the NSABP R04 trial, showed that low, intermediate and high risk of death categories, based on tertiles of the NAR score, were significantly associated with 5-year OS (p < 0.0001) e giving values of 92%, 89%, and 68 %, respectively [7] . Others have also shown lower NAR scores correlate with improved 5-year OS (p < 0$0001) [25] , and outperform pCR [26] . Further studies have shown 5-year overall survival of 84%, 71%, and 59% for low-, intermediate-, and high-risk NAR scores respectively (P ¼ $004) [27] . The NAR score after CRT has recently been validated with individual-level surrogacy according to Prentice criteria for DFS within the CAO/ARO/AIO-04 randomized phase 3 trial, and is approved by the National Cancer Institute as a surrogate primary endpoint in phase II rectal cancer clinical trials assessing neoadjuvant CRT. However, the NAR score has not previously been used to assess outcomes from NACT alone and will require validation.
In BACCHUS, median NAR score in evaluable pts was 14$9 with 5 (28%), 7 (41%), and 5 (30%) patients having low, intermediate, and high NAR scores. These compare favourably with a recent retrospective analysis in patients treated with preoperative CRT, which showed 193/522 (37$0%) had low, 183/522 (35$0%) intermediate, and
146/522 (28$0%) showed high NAR scores [28] . FOLFOXIRI and bevacizumab was particularly active in terms of the NAR score (See Table 6 and Fig. 3 ).
The strengths of BACCHUS reflect the MRI-defined high risk entry criteria, an intensive triplet chemotherapy regimen, the high quality of surgery and a clear definition of the primary endpoint. In this selected high-risk population (making up about 40% of rectal cancers overall) the risk of distant relapse predominates over local recurrence. FOLFOXIRI and bevacizumab is a highly active regimen. A recent meta-analysis of FOLFOXIRI-Bevacizumab studies involving 877 patients in colorectal cancer with initially unresectable metastatic disease reported an objective response rate of 69% (95% CI, 65%e72%; I2 ¼ 25%) [29] . The Neoadjuvant FOL-FOX 6 Chemotherapy With or Without Radiation in Rectal Cancer (FOWARC) trial also suggests that NACT causes less late functional effects than CRT [22, 30] Hence late effects may be expected to be less severe with NACT than after CRT.
However, there are limitations. The trial stopped early because of poor accrual after only 20 patients. Some centres were unwilling to forego CRT. The design of the BACCHUS trial could be criticised for the restrictive patient selection, which limits its applicability to the "real world". An upper age limit of 75 years was mandated with PS 0e1, and current smokers were ineligible. The average of only 1e3 patients per year in individual centres could indicate a significant selection bias towards younger fitter patients.
In BACCHUS, a long interval (6e8 weeks) was mandated between NACT and surgery for safety reasons. The median interval from the end of cytotoxic treatment until surgery was 56 days, but from the final dose of bevacizumab was 72 days (range 20e107 days) in Arm 1 and 86 days (range 30e117 days) in Arm 2 respectively. This delay could have been responsible for less surgical morbidity, there were no anastomotic leaks or pelvic sepsis. However, this interval could also be criticized as being too long, allowing regrowth of the tumour in some patients.
The results of BACCHUS compare favourably with previous NACT studies. The Grupo Español Multidisciplinar en C ancer Digestivo (Gemcad 0801) study achieved a 15% pCR with XELOX þ bevacizumab [13] in an MRI defined population in 46 patients without any radiotherapy. mrEMVI, at baseline was defined in 23/46 (50%) patients compared with 9/20 (45%) in BACCHUS.
However, the GEMCAD 0801 trial reported a higher than expected anastomotic leak rate of 13%, with a 3-to 4-week interval (21e28 days) between completion of chemotherapy and surgery [13] . In a Japanese study, a total 10/30 (43%) patients with LARC treated with XELOX and bevacizumab NACT also developed surgical morbidities [15] .
A feasibility study in a less restricted group of patients (WHO 0e2, no age limit) with clinical stage II-III rectal cancer (but not T4 tumours) used NACT alone with FOLFOX þ Bevacizumab without radiotherapy [16] . R0 resection rate was the primary outcome and pCR was reported in 8/29 resected patients (27%). Surgical morbidity is not described but there was a single postoperative death attributed to dehydration from high-volume ileostomy output. The 4-year DFS rate was 84% and local recurrence was 0% [16] .
Based on these results, a large multi-centre ongoing Phase III study (CALGB PROS-PECT/Allianz N1048 trial) compares standard CRT against chemotherapy using FOLFOX, and examines the selective use of CRT, depending on response to FOL-FOX alone (NCT01515787). The primary endpoints are time to local recurrence and DFS.
Conclusions
As the quality of TME improves, fewer patients with rectal cancer benefit from radiotherapy (which is a local treatment). Hence, the 'blanket use' of radiotherapy is outdated. We need to validate preoperative biomarkers, which predict a high risk of systemic recurrence such as EMVI, and can be imaged on MRI. The potential advantages of NACT in place of RT include the ability to reduce the risk of micrometastases, and to spare patients from the morbidity of pelvic radiotherapy. In future trials, we need to test these biomarkers to estimate prospectively the relative merits of CRT and NACT for the individual.
Previous phase II trials in NACT have had heterogeneous inclusion criteria, few patients and uncertain surgical and MRI quality. The BACCHUS trial shows the delivery of FOLFOXIRI þ Bevacizumab is feasible, safe, and effective in MRI defined high-risk LARC. This triplet combination allows early exposure to an effective systemic regimen, without impacting on compliance or surgical morbidity. Early oncological outcomes in this small number of patients seem promising even in the context of adverse features with EMVI. These findings support ongoing efforts to shift systemic treatments in LARC into the neoadjuvant setting and suggest that delivering neoadjuvant chemotherapy could be as effective as chemoradiation. If high proportions of complete responses and similar NAR scores can be replicated, high-risk patients with locally advanced rectal cancer could have improved survival and simultaneously avoid the harmful effects of pelvic radiation. For this reason, FOL-FOXIRI þ bevacizumab should be explored in a large phase III trial in patients at high risk of systemic relapse and low risk of local relapse against the current standard of routine SCPRT or CRT, and if validated can be translated into an alternative in everyday practice.
